









Markets
/
Stocks
/
nasdaq-gnta
/

Genenta Science SPA

GNTA



View Detailed Chart

2.860USD

-0.020-0.67%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

52.31MMarket Cap

--P/E TTM



Genenta Science SPA

2.860

-0.020-0.67%

Overview Company Financials Analysis

Analysis

Intraday

30m

Today

-0.67%

5 Days

-3.05%

1 Month

-16.23%

6 Months

-25.08%

Year to Date

-34.25%

1 Year

-25.71%

View Detailed Chart

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

271 / 506

Overall Ranking

449 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

21.000

Target Price

+590.79%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including the United States.

Overvalued

The company’s latest PE is -5.86, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 9.06M shares, decreasing 2.79% quarter-over-quarter.